CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 33245-33615 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T160","span":{"begin":0,"end":370},"obj":"Sentence"}],"text":"With regards to respiratory viruses, a small phase I clinical trial in healthy adults investigating a novel MVA-based heterosubtypic influenza A vaccine (MVA NP +M1) demonstrated that all volunteers had a significant increase in the number of IFN-γ producing CD8 T cells in their blood at weeks one, three and eight after intradermal or intramuscular vaccination (109) ."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T160","span":{"begin":0,"end":370},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"With regards to respiratory viruses, a small phase I clinical trial in healthy adults investigating a novel MVA-based heterosubtypic influenza A vaccine (MVA NP +M1) demonstrated that all volunteers had a significant increase in the number of IFN-γ producing CD8 T cells in their blood at weeks one, three and eight after intradermal or intramuscular vaccination (109) ."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T62","span":{"begin":280,"end":285},"obj":"Body_part"}],"attributes":[{"id":"A62","pred":"uberon_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"With regards to respiratory viruses, a small phase I clinical trial in healthy adults investigating a novel MVA-based heterosubtypic influenza A vaccine (MVA NP +M1) demonstrated that all volunteers had a significant increase in the number of IFN-γ producing CD8 T cells in their blood at weeks one, three and eight after intradermal or intramuscular vaccination (109) ."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T128","span":{"begin":108,"end":111},"obj":"Disease"},{"id":"T129","span":{"begin":133,"end":142},"obj":"Disease"},{"id":"T130","span":{"begin":154,"end":157},"obj":"Disease"},{"id":"T25880","span":{"begin":108,"end":111},"obj":"Disease"},{"id":"T36813","span":{"begin":133,"end":142},"obj":"Disease"},{"id":"T3789","span":{"begin":154,"end":157},"obj":"Disease"}],"attributes":[{"id":"A128","pred":"mondo_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/MONDO_0012481"},{"id":"A129","pred":"mondo_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A130","pred":"mondo_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/MONDO_0012481"},{"id":"A58463","pred":"mondo_id","subj":"T25880","obj":"http://purl.obolibrary.org/obo/MONDO_0012481"},{"id":"A19088","pred":"mondo_id","subj":"T36813","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A68003","pred":"mondo_id","subj":"T3789","obj":"http://purl.obolibrary.org/obo/MONDO_0012481"}],"text":"With regards to respiratory viruses, a small phase I clinical trial in healthy adults investigating a novel MVA-based heterosubtypic influenza A vaccine (MVA NP +M1) demonstrated that all volunteers had a significant increase in the number of IFN-γ producing CD8 T cells in their blood at weeks one, three and eight after intradermal or intramuscular vaccination (109) ."}